Healthcare

Duloxetine API Market

By Segment, By Region, And Segment Forecasts, 2015 – 2023

Vertical: HealthcareBase Year: 201713 Sections

Executive Summary

Duloxetine API Market — Snapshot

  • Market Size (2015)

    2015

    $2.91B

  • Projected (2023)

    2023

    $3.98B

  • CAGR (2015–2023)

    4.0%

    4.0%
  • Key Players

    110+

Active pharmaceutical ingredients are used in the manufacturing of pharmaceutical formulations. Duloxetine is a serotonin-norepinephrine reuptake inhibitor used in the treatment of depression and anxiety. Additionally, it is used to help relieve neuropathic pain in people with diabetes or ongoing pain due to medical conditions such as arthritis, chronic back pain, or fibromyalgia. Several factors such as increasing cases of anxiety, the growing prevalence of depression, increasing penetration of generic drugs, the growing trend of outsourcing, strong drug pipeline, and growing demand for newly developed small molecule drugs are anticipated to boost the market growth over the assessment period.

The global duloxetine API was valued at USD 3,213.9 million in 2017, and the market is estimated to grow at USD 3,985.0 million by 2023. In 2017, the Americas accounted for the largest market share of 34.8% with a market value of USD 1,119.1 million, followed by Europe with a market value of USD 975.2 million in 2017.

The global duloxetine API has been segmented based on application and region.

Based on application, the major depressive disorder segment accounted for the largest market share of 33.36% in 2017, with a market value of USD 1,072.1 million, which is projected to register a CAGR of 3.13% during the forecast period.

Key Insight

The Duloxetine API Market market is projected to grow at a CAGR of 4.0% from 2015 to 2023.

Market Performance Trend

Historical performance and future projections (2020–2030, USD Billion)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Scope & Coverage

What this report covers

  • Geographic Coverage: This analysis covers 4 regions: Middle East and Africa, Americas, Asia Pacific, Europe.
  • Market Segmentation: The market is analyzed across key segments with forecasts from 2015 to 2023.
  • Competitive Landscape: 110 leading companies are profiled, covering market positioning, strategies, and recent developments.

Market Size (USD Mn)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Overview

Duloxetine API Market — Growth Trajectory

Duloxetine is a serotonin-norepinephrine reuptake inhibitor used to treat depression, anxiety, and pain. The growing rates of anxiety, the increasing prevalence of depression, rising penetration of generic drugs, and the growing trend of outsourcing are expected to support the market growth over the forecast period. However, changing economic conditions globally and side-effects of duloxetine are likely to hamper the growth of the global duloxetine API market.

Market Size Trend (USD Mn)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Dimensions

How this market is segmented

  • Application Application is broken down into: Major Depressive Disorder, Generalized Anxiety Disorder (GAD), Fibromyalgia, Neuropathic Pain, Chronic Musculoskeletal Pain, Others.

Geographic Analysis

Regional market breakdown

  • Middle East and Africa Middle East and Africa market size reached $199.60M in 2015 and is projected to reach $257.10M by 2023, growing at a CAGR of 3.2%.
  • Americas Americas market size reached $1.00B in 2015 and is projected to reach $1.40B by 2023, growing at a CAGR of 4.3%.
  • Asia Pacific Asia Pacific market size reached $827.10M in 2015 and is projected to reach $1.15B by 2023, growing at a CAGR of 4.2%.
  • Europe Europe market size reached $878.00M in 2015 and is projected to reach $1.17B by 2023, growing at a CAGR of 3.7%.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Research Methodology

Duloxetine API Market — How We Researched This Market

This report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.

  • Base Year

    2017

  • Historical Period

    2015 – 2017

  • Forecast Period

    2017 – 2023

  • Primary Interviews

    150+

Research Process

Historical data (2015–2017) and forecast period (2017–2023)

1

Problem Definition

  • Market scoping
  • Objective setting
  • Framework design
2

Secondary Research

  • Literature review
  • Data mining
  • Trend analysis
3

Primary Research

  • Expert interviews
  • Field visits
  • Surveys
4

Data Analysis

  • Quantitative modeling
  • Statistical testing
  • Validation
5

Insights & Reporting

  • Synthesis
  • Recommendations
  • Visualization

Research Depth

Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.

Historical vs. Forecast Data

Historical (observed)
Forecast (modelled)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Competitive Landscape & Porter's Five Forces

Duloxetine API Market — Competitive Analysis

Threat of New Entrants

The threat of new entrants is high in the global duloxetine API market. In Porter’s Five Forces Analysis, the ‘Threat of New Entrants’ refers to the threat that new competitors pose to existing competitors in an industry. A profitable industry will attract more competitors looking to achieve profits. As the number of entrants increases, the profitability of the present players in the industry subsequently decreases. The global duloxetine API market has a high threat of new entrants, threatening the existing players. Moreover, the cost involved in R&D is comparatively high which does not comfort the new entrants to enter the market easily.

Bargaining Power of Suppliers

Bargaining power of suppliers in the global duloxetine API market is medium. The bargaining power of suppliers estimates how easy it is for the suppliers to influence the prices of the final products made by innovators. Businesses must obtain the necessary resources that they need from the resource suppliers to carry out their activities.

In the global duloxetine API industry, the number of suppliers is comparatively less than the number of firms operating in the sector, and only a few of them have a large hold on the duloxetine API market. The recessionary pressures have reduced the price of many components and raw materials due to downward demand trends. Moreover, the switching cost of these suppliers is also medium as the suppliers tend to enter long-term associations with the manufacturers.

Threat of Substitutes

The threat of substitutes in the global duloxetine API market is medium to low. The substitute to the duloxetine API can only be in the form of large molecules. Buyer propensity to substitute is moderate due to the lesser availability of substitutes in this market. In addition, the high degree of switching cost minimizes the threat of substitutes.

Bargaining Power of Buyers

The bargaining power of the buyer is considered to have a low impact on the industry. The bargaining power of the buyers evaluates how easy it is for the buyers to affect the price of pharmaceutical products. There is a low number of players with capabilities to manufacture high-end drugs.

Also, the high differential advantage of the duloxetine API market coupled with low or poor existing substitutes for high tech products makes the position of the manufacturers strong. However, the latest trend of mergers between large healthcare providers coupled with strategies such as demand pooling by multiple players is increasing the power of the buyers.

Intensity of Rivalry

The degree of competition in the global duloxetine API market is high. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. The intensity of competitive rivalry evaluates the capability and the level of rivalry among competitors in the market. It also refers to the extent to which firms within an industry put pressure on one another and limit each other’s profit potential. Rivalry among industry players can affect industry profits through downward pressure on prices, increased innovation, increased advertising, and increased service/product improvements, among others.

Quantitative Analysis

Regional Breakdown

Regional market breakdown for Duloxetine API Market.

Regional Market Size (USD Mn)

Market estimates by geography (2023)

USD Mn

InsightAmericas leads with $1.40B by 2023.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Regional Market Data

REGION201520172023CAGRSHARE
Middle East and Africa$199.60M$239.40M$257.10M3.2%6%
Americas$1.00B$1.22B$1.40B4.3%35%
Asia Pacific$827.10M$964.40M$1.15B4.2%29%
Europe$878.00M$1.06B$1.17B3.7%29%
Total$2.91B$3.49B$3.98B4.0%100%

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans
Empower your Business
with Insights

Save over 20% on
Annual Subscription

See plans for professionals or small and medium businesses.

Wantstats analytics dashboard

Analytics

Duloxetine API Market — Key Findings

Analytical insights on Duloxetine API Market covering market dynamics, competitive landscape, and strategic outlook.

Key Analytical Findings

The Duloxetine API Market market is projected to reach $3.98B by 2023, growing at 4.0% CAGR.

Market Dynamics

The duloxetine drug primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), and pain related to diabetic peripheral neuropathy, among others. Factors such as the rising rates of anxiety cases, increasing prevalence rates of depression, increasing penetration of generic versions of drugs, strong drug pipeline, growing demand for newly developed small molecule drugs, and the growing trend of outsourcing are major drivers propelling market growth.

Market Drivers

The people suffering from anxiety are increasing at a fast pace. According to a report by the World Health Organization (WHO), the portion of the global population with anxiety disorders was estimated to be 3.6% in 2015. It also stated that in 2015 the total estimated number of people living with anxiety disorders globally was about 264 million. According to the same source, in 2015, about 36.17 million cases of anxiety disorders were reported in the European region. Moreover, according to the updated report by the Anxiety and Depression Association of America, in 2017, approximately 30% of the adult population in North America had anxiety disorders. Therefore, as duloxetine is used to treat anxiety cases, the increasing prevalence of anxiety is expected to provide favorable background for the market to grow over the forecast period.

Market Opportunities

Over the past years, the pharmaceutical industry has been focusing more on the development of biologics. As a result, the API market has suffered tremendous regression. Many custom manufacturing organizations (CMOs) have shifted their focus to high-value biologics manufacturing.

Nevertheless, the attention of the pharmaceutical industry seems to be back with small molecule therapeutics. Many companies have come up with generic versions of duloxetine. For instance, in June 2014, Dr. Reddy's Laboratories launched duloxetine delayed-release capsule United States Pharmacopeia (USP) 20 mg, 30 mg, and 60 mg in the US market. Thus, the growing worldwide demand for effective drugs and the upcoming launch of several blockbuster drugs would create more opportunities in the near future.

Market Restraints

Austerity measures in Europe are putting pressures on margins for drug manufacturers. For instance, in the past, Germany has implemented a free price-setting mechanism which had led pharma companies to enjoy high prices of patented pharmaceutical products. But since the economic downfall in the region, Germany started seeking chances to curb its expenses and to control the increasing pharmaceutical spending. The country passed the act for restructuring the pharmaceutical market in statutory health insurance which came into effect in 2011. According to the regulation, pharmaceutical manufacturers must demonstrate the additional therapeutic benefit of newly approved pharmaceuticals compared to their competitors.

Furthermore, German drug prices are frequently used as a reference point by healthcare providers in other European countries. This has put severe pricing pressures on drug manufacturers which led many to look for alternative ways to decrease their cost of manufacturing to survive in the harsh market. The economic condition in Europe is a major factor of worry for the growth of the global duloxetine API market.

Strategic Outlook and Future Directions

Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.

Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.

Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.

Companies

Key companies profiled in Duloxetine API Market

Profiles of 110 companies operating in the Duloxetine API Market market, including revenue, employee count, and market positioning where available.

Showing 110 of 110 companies

Shionogi I

Shionogi Inc.

Healthcare

Company Headquarters: Osaka, Japan Founded: 1878 Company Working: Shionogi Inc. is a development organization capable of conducting multiple simultaneous late-stage clinical programs and submitting new drug application (NDA) filings worldwide. The company has established commercial capabilities to market their products globally effectively.

Revenue$2.2B
EmployeesN/A
Market CapN/A
Founded1877
Osaka, Japan
Apotex Inc

Apotex Inc.

Healthcare

Company Headquarters: Canada Founded: 1974 Workforce: 10,000+ Company Working: Apotex Inc. (Apotex) is the largest Canadian-owned pharmaceutical company. It is also the largest producer of generic medicines in the country. Apotex is a global, fully integrated API R&D company. It has many facilities across the globe located in Canada, India, Mexico, and China. The Apotex Group of Companies is comprised of Apotex Generics, Apotex Active Pharmaceutical Ingredients, Apobiologix, and ApoPharma (Innovative Products) through vertical integration. The company exports to more than 115 countries and operates in more than 45 countries. Globally, it produces approximately 25 billion doses per year, which are used to fill over 89 million prescriptions in Canada alone. Apotex is into unit dose products, injectable products, and specialty products.

RevenueN/A
Employees10,000
Market CapN/A
Founded1973
Canada
Hetero

Hetero

Healthcare

Company Headquarters: Hyderabad, India Founded: 1997 Workforce: 10 Company Working: Hetero is a research-based global pharmaceutical company focused on the development, manufacturing, and marketing of active pharmaceutical ingredients (API), intermediate chemicals, and finished dosages. The company is vertically integrated for research discovery, process chemistry, API manufacturing, formulation development, and commercialization. It is an international supplier of over 200 products from a wide range of therapeutic categories. Majority of them are approved by various regulatory authorities of the USFDA, WHO-Geneva, Australian TGA, Spanish agency of medicines & health care products, ANVISA-Brazil, IDA-Netherlands, etc. It markets its products in over 138 countries across the globe.

RevenueN/A
Employees10
Market CapN/A
Founded1996
Hyderabad, India
Shodhana L

Shodhana Laboratories Ltd

Healthcare

Company Headquarters: Hyderabad, India Founded: 2000 Workforce: ~700 Company Working: Shodhana Laboratories Ltd (Shodhana) is an active pharmaceutical ingredients and intermediates manufacturing company. The company caters to both domestic and global markets. Shodhana is engaged in manufacturing and marketing bulk actives, pharma chemicals, and ingredients for pharmaceutical applications. It manufactures a wide range of products in the areas of antidepressant, anti-emetic, anti-anginal, anti-Parkinson, anti-diarrheal, anti-hypertensive, and beta-adrenergic, amongst others. Some of the products manufactured by Shodhana include Carvedilol, Mizolastine, Carbidopa, Racecadotril, Rivastigmine, Ondansetron, Ranolazine, Escitalopram Oxalate, Citalopram Hydrobromide, Escitalopram Oxalate, Dapoxetine Hydrochloride, and others. It exports its products to over 50 countries.

RevenueN/A
Employees700
Market CapN/A
Founded1999
Hyderabad, India
Zydus Cadi

Zydus Cadila

Healthcare

Company Headquarters: Ahmedabad, India Founded: 1952 Workforce: 23,000+ Company Working: Zydus Cadila is one of the leading Indian pharmaceutical companies. It has in-depth domain expertise in the field of healthcare. It also has strong capabilities across the range of the pharmaceutical value chain. The company provides comprehensive and complete healthcare solutions ranging from formulations to APIs and animal healthcare products to wellness products. Its presence spreads across four continents. The company ranks fourth in the Indian pharmaceutical industry with manufacturing and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim. Globally, Zydus Cadila has a strong presence in regulated markets of the US, Europe (France and Spain), and the high-profile markets of Latin America and South Africa. It also has a strong presence in 25 other emerging markets worldwide.

Revenue$1.4B
Employees23,000
Market CapN/A
Founded1951
Ahmedabad, India
Eli Lilly

Eli Lilly and Company

Healthcare

Company Headquarter: ‎ Indianapolis, Indiana, US Founded: 1876 Workforce: 42,066 Company Working: Eli Lilly and Company is an American global pharmaceutical company. The company also has offices in Puerto Rico and 17 other countries. Its products are sold in approximately 125 countries. The company is listed on the New York Stock Exchange, and its shares had been a component of the S&P 500 Index since 1971. Lilly was the first company to mass-produce penicillin, the Salk polio vaccine, and insulin. Its achievements include being one of the first pharmaceutical companies to produce human insulin using recombinant DNA including Humulin, Humalog, and the first approved biosimilar insulin product in the US, Basaglar. Lilly is also the world's largest manufacturer and distributor of psychiatric medications including Prozac (Fluoxetine), Dolophine (Methadone), Cymbalta (Duloxetine), and Zyprexa (olanzapine). Some of the top competitors of Eli Lilly and Company are Pfizer Inc., GlaxoSmithKline PLC, Biogen, Sanofi, and Johnson and Johnson.

Revenue$21.2B
Employees42,066
Market CapN/A
Founded1875
United States, North America
Page 1 of 19
Go to page

About the Author

Healthcare Research Team

Healthcare

Our healthcare desk at Wantstats is staffed by a mix of clinical-market analysts and a senior researcher who track drug approvals, device launches, and provider economics as they happen — not just at reporting time. Every figure in this report is checked against primary interviews, regulatory filings, and our own proprietary datasets before it goes to print.

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Duloxetine API Market

Starting from
$4,950